MacroGenics, Inc. logo

MacroGenics, Inc.

NASDAQ:MGNX

Overview | Financials
Company Name MacroGenics, Inc.
Symbol MGNX
Currency USD
Price 3.7
Market Cap 232,072,140
Dividend Yield 0%
52-week-range 3.14 - 21.88
Industry Biotechnology
Sector Healthcare
CEO Dr. Scott Koenig M.D., Ph.D.
Website https://www.macrogenics.com

An error occurred while fetching data.

About MacroGenics, Inc.

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who

Related Stocks

Viemed Healthcare, Inc. logo

Viemed Healthcare, Inc.

VMD

7.59 USD

Zentek Ltd. logo

Zentek Ltd.

ZTEK

1.25 USD

VBI Vaccines Inc. logo

VBI Vaccines Inc.

VBIV

0.065 USD

The Joint Corp. logo

The Joint Corp.

JYNT

12 USD

Cogent Biosciences, Inc. logo

Cogent Biosciences, Inc.

COGT

10.63 USD

KalVista Pharmaceuticals, Inc. logo

KalVista Pharmaceuticals, Inc.

KALV

11.14 USD

Liquidia Corporation logo

Liquidia Corporation

LQDA

9.795 USD

VistaGen Therapeutics, Inc. logo

VistaGen Therapeutics, Inc.

VTGN

3.29 USD

Prelude Therapeutics Incorporated logo

Prelude Therapeutics Incorporated

PRLD

2.77 USD

Financials

Numbers are in millions USD

Numbers are in millions USD